e365593cd3d7df9b8d32b8c7dc327ea09feedec8ca9ef5c482f2f429b5542384  ./cv_fold02_train_summary.md
633892a04c0473f68252fa3882201f8609c8d1fe0f8c847118af14c17818b220  ./denoised_full_run.csv
a6a00bc792abcb761e8f152de9e9b8ca6d674fb090bdd95a6ab5bdfb705a744c  ./manifests/fold_01/test_manifest.csv
f4a6524f4e0fbedc97e5c4718d9126c46b19ecf1d338a8d1444efa3e893fa164  ./manifests/fold_01/train_manifest.csv
433ea4497764b8040a7d652b5d1a6847eb7b6636c233b69dadf697fb04983d43  ./manifests/fold_01/val_manifest.csv
fed6b0cdff2d6cf7bb3cee875a86930f63007ef084df0c68087a86803aaa8de6  ./manifests/fold_02/test_manifest.csv
fa62c52386d776d6cc5daf30c66ebca4f5e638d81815fb2ea90ee2ba291b0f47  ./manifests/fold_02/train_manifest.csv
a6a00bc792abcb761e8f152de9e9b8ca6d674fb090bdd95a6ab5bdfb705a744c  ./manifests/fold_02/val_manifest.csv
e3f612a3dd8c97fe03df5b462eb718d790b3d6b0442b69a6fd7fe8967f6ac811  ./manifests/fold_03/test_manifest.csv
a20dba71d12b06b9ddc4f460ffa238152acf0851ba274ecad6a2db2320d943f7  ./manifests/fold_03/train_manifest.csv
fed6b0cdff2d6cf7bb3cee875a86930f63007ef084df0c68087a86803aaa8de6  ./manifests/fold_03/val_manifest.csv
ee00c02369e106cc00cd6179961fac3385980213c82459d73fb44584abd96f30  ./manifests/fold_04/test_manifest.csv
4c27aa76c0f92162431ac9918558926633954f2bf1a777b337d03a45a7d99988  ./manifests/fold_04/train_manifest.csv
e3f612a3dd8c97fe03df5b462eb718d790b3d6b0442b69a6fd7fe8967f6ac811  ./manifests/fold_04/val_manifest.csv
433ea4497764b8040a7d652b5d1a6847eb7b6636c233b69dadf697fb04983d43  ./manifests/fold_05/test_manifest.csv
4a9ba69500de7c2568945ce8416499736bbe71ea70fadf76b69a349d458a6e62  ./manifests/fold_05/train_manifest.csv
ee00c02369e106cc00cd6179961fac3385980213c82459d73fb44584abd96f30  ./manifests/fold_05/val_manifest.csv
f5575f037dd4a79151f1fbccd4c313350e4c8205d4fd38dc16722942f4b71989  ./metadata/dose_features.csv
e30dd66fe3ff88da1d514a22dc4eb801cf25867dcf5a871c677899b549cd8c7e  ./metadata/dose_features.csv.bak
26143529cf4c30bc13dbcbe048e1998781165ee38ed260b2e2d91283f12692d3  ./metadata/dose_sampling_weights.csv
e0a7659922f0d70b06879529166af2642c149ddb30eef9611673a3d2f99de1dd  ./metadata/dose_sampling_weights.csv.bak
89caf057d624dfbda2e789da6216c7b5c36f868692f3d85f1fbaac01d38df249  ./metadata/dose_sampling_weights.csv.pre_merged
82a3ecf169567119398a97742c5bcd23dc79f86810d20b19658da7e1971b23f9  ./metadata/dose_stats.json
63f9868ef61aece2f0c5fa8d8b7c227232d7e8da48320522fe39e8d674de6031  ./metadata/README.md
659df4db0e4a12e332f94dee1b9df52b7afe59b0cc9e0aacdac89ac0c27982d3  ./README.md
d0516d2d4b63e5981c8645c6f332dfad2b2e0438d9e203acea79ff33e8c1defd  ./train_manifest_summary.md
f77ab5b072d6f0bfd186a719641fd68d36ce90a1a0f6b049f6509d5c6c1ff186  ./training_group_counts.md
6fd21149c08f911cb9a868eee4ec3f5e20f502432eff7de6a652c4aed98c1b28  ./validation_panel_summary.md
10d6c12bb8dd61fc17596956010771d76ba21ed7aeacd57dddc8e29ccb12e7fe  ./validation_panel.csv
